← Patent-cliff monitor small molecule LENVIMA LENVATINIB MESYLATE
Loss of exclusivity November 2038 latest FDA-listed patent expiry
Company Eisai → See this company's full patent-cliff portfolio Drug detail Brand name LENVIMA Active ingredient LENVATINIB MESYLATE Strength EQ 10MG BASE Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval February 2015 Marketing status RX
Listed patents Patent Expires Type 12226409*PED November 2038 — 12226409 May 2038 use U-4146 12083112*PED September 2036 — 11090386*PED August 2036 — 12083112 March 2036 use U-3997 10259791*PED February 2036 — 10407393*PED February 2036 — 11186547*PED February 2036 — 11090386 February 2036 use U-3519 11186547 August 2035 substance 10407393 August 2035 substance 10259791 August 2035 substance 12508313*PED April 2031 — 12508313 October 2030 product 9006256*PED January 2028 — 9006256 July 2027 use U-1695 7612208*PED March 2027 — 7612208 September 2026 substance, product 7253286*PED April 2026 — 7253286 October 2025 substance, product
Regulatory exclusivity Code Expires PED October 2027 M-14 April 2027 PED February 2026 ODE-196 August 2025
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.